Form 4: Starovasnik Sells Twist Bioscience Shares
Insider Transaction Report
Melissa A. Starovasnik, a Director at Twist Bioscience Corp, reported a sale of 2,500 common shares on May 28, 2026, executed under a pre-established Rule 10b5-1 trading plan.
Summary
- Melissa A. Starovasnik, a Director at Twist Bioscience Corporation (TWST), has reported a transaction involving company stock.
- On May 28, 2026, 2,500 shares of common stock were disposed of at a price of $68 per share.
- Following this transaction, Ms. Starovasnik beneficially owns 22,222 shares of common stock directly.
- The sale was conducted as part of a Rule 10b5-1 trading plan, adopted on November 22, 2025, which is designed to satisfy affirmative defense conditions for insider trading.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While a director selling shares can sometimes be perceived negatively, the transaction was conducted under a pre-arranged Rule 10b5-1 plan, mitigating concerns about insider trading and suggesting a planned divestment rather than a reaction to negative company news.
Negatives
- A Director has sold a portion of their holdings in the company.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates a structured approach to stock sales, often employed by executives to diversify holdings or meet financial obligations without violating insider trading regulations. This specific transaction by a director at Twist Bioscience is a routine event for publicly traded companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan | The transaction was executed under a Rule 10b5-1 trading plan adopted on November 22, 2025. | 11/22/2025 | Demonstrates adherence to established procedures for insider stock transactions, aiming to provide an affirmative defense against allegations of insider trading. |
Stakeholder Impact
- Shareholders: The sale of shares by a director may lead to short-term investor sentiment shifts, though the use of a Rule 10b5-1 plan aims to reduce negative implications.
- Management: Reinforces the established procedures for executive stock transactions and compliance with regulatory requirements.
Key Dates
| Date | Description |
|---|---|
| 11/22/2025 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 05/28/2026 | Date of the reported transaction (sale of common stock). |
| 06/01/2026 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Stock Sale, Director Transaction, Twist Bioscience, TWST
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.